Acuitive Technologies receives FDA 510(k) clearance of bioactive bone void filler
Click Here to Manage Email Alerts
Key takeaways:
- Acuitive Technologies announced FDA clearance for Citrepore, a synthetic bioactive bone void filler.
- Citrepore is indicated to promote natural bone healing in patients who undergo orthopedic surgery.
Acuitive Technologies Inc. announced FDA 510(k) clearance for Citrepore, a synthetic bioactive bone void filler designed to promote bone healing after orthopedic surgical procedures, according to a company press release.
Citrepore is an osteoconductive and bioactive bone filler, which has 80% porosity to allow resorption of saline, blood and bone marrow aspirate, and promotes natural bone healing in orthopedic patients, according to the release.
“Citrate, a critical intermediate in the Krebs cycle, is highly concentrated in native bone and is closely associated with bone metabolism and formation,” Richard Tran, PhD, vice president of research at Acuitive Technologies, said in the release. “In response to citrate, human stem cells increase genetic signaling for metabolism, osteoinduction, osteoconduction and extracellular matrix production.”
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts